aTYR PHARMA INC
Current- Director 2019 to present
Skip to record
Executive record
Alpha ID: alpha:person:svetlana-lucasVersion: public-0As of: 2026-09-30
Not yet claimed11 published Claims5 sources
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Svetlana Lucas currently serves as Chief Business Officer at Scribe Therapeutics, a private genetic medicines company. She has extensive business development experience in the biotherapeutics industry, previously serving as Senior Vice President of Business Development at Tizona Therapeutics and Head of Oncology and Inflammation External R&D at Amgen.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Executive career
- 2026 to end not publishedExecutive title: Vice President, Controller and Chief Accounting Officer · Organization not publishedRDI 10-K executive officers
- Dates not publishedExecutive title: Chief Business Officer · Organization not publishedATYR DEF 14A director slate
Claims
Compensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
5 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
RDIB 10-K executive officers
sec filing · Source published: Mar 31, 2026 · Retrieved: Jul 28, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at READING INTERNATIONAL INC · Claim reviewed: Jul 28, 2026
- Executive title: Executive title: Vice President, Controller and Chief Accounting Officer · Claim reviewed: Jul 28, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026
RDI 10-K executive officers
sec filing · Source published: Mar 31, 2026 · Retrieved: May 16, 2026
Supports 2 claims
- Executive company: Executive at READING INTERNATIONAL INC · Claim reviewed: Jul 28, 2026
- Executive title: Executive title: Vice President, Controller and Chief Accounting Officer · Claim reviewed: Jul 28, 2026
ATYR DEF 14A director slate
sec filing · Source published: Mar 26, 2026 · Retrieved: May 15, 2026
Supports 7 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Board role: Board role: Director · Claim reviewed: May 15, 2026
- Committee assignments: Committee assignments: Audit, Nominating/Governance · Claim reviewed: May 15, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
- Executive company: Executive at Scribe Therapeutics · Claim reviewed: May 15, 2026
- Executive title: Executive title: Chief Business Officer · Claim reviewed: May 15, 2026
- Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026
Open source
sec proxy · Source published: Mar 26, 2026 · Retrieved: Apr 24, 2026
Supports 1 claim
- Professional Role: Director at aTYR PHARMA INC · Claim reviewed: May 16, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of aTYR PHARMA INC · Claim reviewed: May 16, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-09-30
- Biography
- published
- Board service
- published
- Executive career
- published
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- not observed
- Background screening
- out of scope